Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Resistant Progressive Interstitial Pneumonitis
NCT02251964Phase 3Completed
- Start
- Sep 2014
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in interstitial pneumonitis. Started Sep 2014; status: completed.
02
Drugs
rituximab
03
Conditions
interstitial pneumonitis
Beyond the preview
Go deeper on NCT02251964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251964.